(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2011 (30.06.2011)

PCT

(10) International Publication Number
WO 2011/077309 A2

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 14/705* (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:
PCT/IB2010/055674

(22) International Filing Date:
8 December 2010 (08.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/289,083 22 December 2009 (22.12.2009) US

(71) Applicant *(for all designated States except US)*: **PFIZER VACCINES LLC** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AHMED, Syed Saleem** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **BUCKLEY III, John Joseph** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **LEWIS, Lavinia Marina** [IN/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **OSBORNE, Brandi Rae** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **SINHA, Sandipan** [IN/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **THORN, Jennifer Marie** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **ZAMAN, Ferhana** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US).

(74) Agents: **NELSON MULLINS RILEY & SCARBOROUGH LLP** et al.; One Post Office Square, Boston, MA 02109-2127 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: VACCINE COMPOSITIONS

(57) Abstract: The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the compositions described herein.

WO 2011/077309 A2